{"hands_on_practices": [{"introduction": "Effective management of lupus nephritis begins with accurately identifying the underlying renal syndrome from the initial clinical presentation. This practice challenges you to synthesize a patient's symptoms and laboratory data to distinguish between a nephrotic and nephritic process. By connecting the classic features of nephrotic syndrome to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification, this exercise hones the fundamental skill of predicting the most likely non-proliferative pathology and anticipating its immediate, life-threatening complications [@problem_id:4865001].", "problem": "A patient with known systemic lupus erythematosus presents with progressive bilateral lower-extremity edema. Vital signs are stable without respiratory distress. Laboratory testing shows serum albumin $2.1\\ \\mathrm{g/dL}$, a spot urine protein-to-creatinine (UPC) ratio of $6.0\\ \\mathrm{g/g}$, and a serum creatinine of $0.8\\ \\mathrm{mg/dL}$. Urinalysis reveals proteinuria with few cells, no red blood cell casts, and occasional oval fat bodies. Complement levels are low and anti–double-stranded deoxyribonucleic acid (anti–dsDNA) titers are elevated. Based only on fundamental definitions distinguishing nephrotic versus nephritic syndromes and the International Society of Nephrology/Renal Pathology Society (ISN/RPS) lupus nephritis classification, select the most likely lupus nephritis class and the most immediate complications to anticipate in the coming days.\n\nA. Class V (membranous) lupus nephritis; venous thromboembolism (including renal vein thrombosis) and infections with encapsulated organisms\n\nB. Class III (focal proliferative) lupus nephritis; rapidly progressive crescentic glomerulonephritis with abrupt rise in creatinine and gross hematuria as the dominant immediate risk\n\nC. Class II (mesangial proliferative) lupus nephritis; isolated microscopic hematuria without nephrotic complications and no increased thrombotic risk\n\nD. Class IV (diffuse proliferative) lupus nephritis; hypertensive emergency and abrupt decline in glomerular filtration rate due to nephritic syndrome with red blood cell casts\n\nE. Mixed Class III + V lupus nephritis; diffuse pulmonary hemorrhage as the highest immediate risk due to renal-limited inflammation", "solution": "The problem statement will be validated by first extracting the given information and then assessing its scientific validity and coherence.\n\n### Step 1: Extract Givens\n- **Patient History:** Known systemic lupus erythematosus (SLE).\n- **Clinical Presentation:** Progressive bilateral lower-extremity edema.\n- **Vital Signs:** Stable, no respiratory distress.\n- **Laboratory Findings:**\n    - Serum albumin: $2.1\\ \\mathrm{g/dL}$.\n    - Spot urine protein-to-creatinine (UPC) ratio: $6.0\\ \\mathrm{g/g}$.\n    - Serum creatinine: $0.8\\ \\mathrm{mg/dL}$.\n- **Urinalysis Findings:**\n    - Proteinuria.\n    - Few cells.\n    - No red blood cell (RBC) casts.\n    - Occasional oval fat bodies.\n- **Serological Markers:**\n    - Low complement levels.\n    - Elevated anti–double-stranded deoxyribonucleic acid (anti–dsDNA) titers.\n- **Question:** Identify the most likely International Society of Nephrology/Renal Pathology Society (ISN/RPS) lupus nephritis class and the most immediate complications to anticipate.\n\n### Step 2: Validate Using Extracted Givens\nThe problem provides a self-contained clinical vignette.\n- **Scientific Grounding:** The presentation is a classic example of renal involvement in SLE. The provided laboratory values, urinalysis results, and serological markers are consistent with established pathophysiology. Systemic lupus erythematosus is a known cause of various forms of glomerulonephritis. The use of the ISN/RPS classification is the current standard of care. The data points are scientifically and medically sound.\n- **Well-Posedness:** The problem is well-posed. It presents a clear clinical scenario and asks for the most probable diagnosis and associated risks based on the data. In clinical medicine, decisions are often based on probabilistic reasoning (\"most likely\") pending definitive tests like a biopsy. The given information is sufficient to construct a strong differential diagnosis and identify the leading candidate.\n- **Objectivity:** The description uses objective clinical and laboratory data. There are no subjective or ambiguous terms.\n- **Consistency and Completeness:** The data are internally consistent. The massive proteinuria (UPC of $6.0\\ \\mathrm{g/g}$) logically explains the severe hypoalbuminemia (serum albumin of $2.1\\ \\mathrm{g/dL}$), which in turn causes the prominent edema. The presence of oval fat bodies is a direct consequence of hyperlipidemia secondary to nephrotic syndrome, confirming lipiduria. A normal serum creatinine ($0.8\\ \\mathrm{mg/dL}$) and a bland urinary sediment (no RBC casts) are consistent with a non-proliferative, non-inflammatory glomerular process. Low complements and high anti-dsDNA titers confirm active lupus as the underlying etiology. The problem is complete for the task of inferring the most likely clinical-pathological entity.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. It is scientifically grounded, well-posed, objective, and internally consistent. I will proceed with the solution derivation.\n\n### Derivation of the Solution\n\n**1. Characterization of the Renal Syndrome:**\nThe patient's clinical and laboratory findings must be synthesized to define the renal syndrome. Nephrotic syndrome is characterized by the following features:\n- **Massive proteinuria:** Conventionally defined as protein excretion $3.5\\ \\mathrm{g}$ per $1.73\\ \\mathrm{m}^2$ per $24\\ \\mathrm{hours}$. The patient's spot urine protein-to-creatinine ratio of $6.0\\ \\mathrm{g/g}$ is a reliable estimate of daily protein excretion and is well within the nephrotic range (approximately $6.0\\ \\mathrm{g/day}$).\n- **Hypoalbuminemia:** A serum albumin level less than $3.5\\ \\mathrm{g/dL}$. The patient's value of $2.1\\ \\mathrm{g/dL}$ is severely low, consistent with massive urinary protein loss.\n- **Edema:** The patient's bilateral lower-extremity edema is a direct consequence of the reduced plasma oncotic pressure from hypoalbuminemia.\n- **Hyperlipidemia and Lipiduria:** The presence of oval fat bodies in the urine is pathognomonic for lipiduria, which reflects the underlying hyperlipidemia of nephrotic syndrome.\n\nIn contrast, nephritic syndrome is characterized by glomerular inflammation, leading to hematuria (especially with RBC casts), hypertension, and acute renal failure (rising creatinine). This patient's serum creatinine is normal ($0.8\\ \\mathrm{mg/dL}$), and the urinalysis notably lacks RBC casts, indicating an absence of significant glomerular inflammation.\n\nTherefore, the patient's presentation is a classic, pure **nephrotic syndrome**.\n\n**2. Correlation with ISN/RPS Lupus Nephritis Classification:**\nThe ISN/RPS classification links histological findings to clinical syndromes.\n- **Class I (Minimal Mesangial)** and **Class II (Mesangial Proliferative)** are associated with minimal or mild proteinuria and/or hematuria, not severe nephrotic syndrome.\n- **Class III (Focal Proliferative)** and **Class IV (Diffuse Proliferative)** are inflammatory and proliferative lesions. They are the classic causes of nephritic syndrome or mixed nephrotic-nephritic pictures, typically presenting with an active urinary sediment (RBCs, RBC casts) and a decline in renal function. This is inconsistent with the patient's bland sediment and normal creatinine.\n- **Class V (Membranous)** is characterized by immune complex deposition in the subepithelial space, leading to podocyte injury and disruption of the glomerular filtration barrier. The classic clinical presentation is a pure nephrotic syndrome with a bland urinary sediment and preserved renal function, at least initially. This perfectly matches the patient's presentation.\n- **Class VI (Advanced Sclerosing)** represents end-stage kidney disease with irreversible scarring and would present with a high creatinine and low glomerular filtration rate.\n\nBased on this analysis, the most likely histological lesion is **Class V (membranous) lupus nephritis**.\n\n**3. Identification of Immediate Complications:**\nThe immediate, life-threatening complications of severe nephrotic syndrome are a direct result of the massive loss of plasma proteins in the urine.\n- **Thromboembolism:** This is a paramount concern. The urinary loss of anticoagulant proteins (e.g., antithrombin III) and the compensatory hepatic overproduction of procoagulant factors (e.g., fibrinogen) create a profound hypercoagulable state. The risk is inversely proportional to the serum albumin level and is significantly elevated when serum albumin falls below $2.5\\ \\mathrm{g/dL}$. This patient's albumin is $2.1\\ \\mathrm{g/dL}$, placing them at very high risk for venous thromboembolism (VTE), which includes deep vein thrombosis, pulmonary embolism, and the classically associated renal vein thrombosis.\n- **Infection:** Patients are immunodeficient due to the urinary loss of immunoglobulins (IgG) and complement components, impairing opsonization and humoral immunity. This increases susceptibility to serious bacterial infections, particularly with encapsulated organisms like *Streptococcus pneumoniae*.\n\nThese two complications—thromboembolism and infection—represent the most immediate threats to the patient in the coming days.\n\n### Evaluation of Options\n\n**A. Class V (membranous) lupus nephritis; venous thromboembolism (including renal vein thrombosis) and infections with encapsulated organisms**\n- **Lupus Nephritis Class:** This correctly identifies Class V as the most likely diagnosis based on the pure nephrotic syndrome presentation.\n- **Complications:** This correctly identifies the two most critical and immediate complications of severe nephrotic syndrome: hypercoagulability leading to VTE and immunodeficiency leading to infections.\n- **Verdict:** **Correct**.\n\n**B. Class III (focal proliferative) lupus nephritis; rapidly progressive crescentic glomerulonephritis with abrupt rise in creatinine and gross hematuria as the dominant immediate risk**\n- **Lupus Nephritis Class:** This is incorrect. Class III is a proliferative nephritis that typically causes an active, nephritic picture, which this patient does not have.\n- **Complications:** The described complications are those of a severe nephritic flare, which is contrary to the clinical data (normal creatinine, no RBC casts).\n- **Verdict:** **Incorrect**.\n\n**C. Class II (mesangial proliferative) lupus nephritis; isolated microscopic hematuria without nephrotic complications and no increased thrombotic risk**\n- **Lupus Nephritis Class:** This is incorrect. Class II is associated with a much milder clinical picture and does not cause severe nephrotic syndrome.\n- **Complications:** The statement \"without nephrotic complications and no increased thrombotic risk\" is a direct contradiction of the patient's actual state.\n- **Verdict:** **Incorrect**.\n\n**D. Class IV (diffuse proliferative) lupus nephritis; hypertensive emergency and abrupt decline in glomerular filtration rate due to nephritic syndrome with red blood cell casts**\n- **Lupus Nephritis Class:** This is incorrect. Class IV is a severe proliferative nephritis associated with a prominent nephritic syndrome, which is absent in this patient.\n- **Complications:** The patient's stable vital signs, normal creatinine, and lack of RBC casts contradict the described complications.\n- **Verdict:** **Incorrect**.\n\n**E. Mixed Class III + V lupus nephritis; diffuse pulmonary hemorrhage as the highest immediate risk due to renal-limited inflammation**\n- **Lupus Nephritis Class:** While mixed classes exist, the patient's purely nephrotic presentation makes a pure Class V lesion most likely. A mixed class would often have some nephritic features.\n- **Complications:** Diffuse pulmonary hemorrhage is a potential severe manifestation of SLE but is not a direct or most common complication of the nephrotic state itself. The most immediate and probable risks stem from the consequences of massive proteinuria, i.e., thromboembolism and infection. The phrase \"renal-limited inflammation\" is also contradictory in the context of pulmonary hemorrhage.\n- **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4865001"}, {"introduction": "Modern treatment of lupus nephritis is guided by a \"treat-to-target\" approach, where early and objective measures of response predict long-term renal outcomes. This exercise provides a hands-on opportunity to apply this principle by calculating the fractional reduction in proteinuria for a patient undergoing therapy. You will use a hypothetical but clinically relevant set of criteria to determine if the patient has achieved an early partial renal response, a critical skill for monitoring treatment efficacy and making timely adjustments to a patient's care plan [@problem_id:4864995].", "problem": "A patient with systemic lupus erythematosus (SLE) and biopsy-proven proliferative lupus nephritis initiates immunosuppressive therapy. The urinary protein-to-creatinine ratio (UPC) is used as a dimensionless estimator of daily protein excretion. At baseline, the UPC is $3.5$, and the estimated glomerular filtration rate (eGFR) is $68$ mL/min per $1.73$ m$^{2}$. After $12$ weeks of therapy, the UPC is $1.2$, and the eGFR is $66$ mL/min per $1.73$ m$^{2}$. For the purposes of this exercise, define the fractional reduction in proteinuria, $r$, as the relative decrease from baseline given by $r = \\dfrac{x_{0} - x_{12}}{x_{0}}$, where $x_{0}$ is the baseline UPC and $x_{12}$ is the $12$-week UPC. Assume a working definition of early partial renal response that requires all of the following to be true simultaneously: (i) $r \\geq 0.5$, (ii) $x_{12}  3.0$, and (iii) the relative decline in eGFR is less than $0.2$ of baseline over the same interval. Starting only from the definition of relative change and the given response criteria, compute $r$ and determine whether the patient meets the partial response criterion at $12$ weeks. Report only the value of $r$ as a decimal (not with a percent sign), rounded to four significant figures. No units are required for $r$.", "solution": "The problem statement has been validated and is deemed valid. It is scientifically grounded, well-posed, objective, and contains all necessary information to arrive at a unique solution.\n\nThe primary task is to compute the fractional reduction in proteinuria, $r$, and determine if the patient meets the criteria for an early partial renal response. The given data are:\n- Baseline urinary protein-to-creatinine ratio (UPC): $x_{0} = 3.5$\n- $12$-week UPC: $x_{12} = 1.2$\n- Baseline estimated glomerular filtration rate (eGFR): $g_{0} = 68$ mL/min per $1.73$ m$^{2}$\n- $12$-week eGFR: $g_{12} = 66$ mL/min per $1.73$ m$^{2}$\n\nFirst, we compute the fractional reduction in proteinuria, $r$, using the provided definition:\n$$r = \\frac{x_{0} - x_{12}}{x_{0}}$$\nSubstituting the given values:\n$$r = \\frac{3.5 - 1.2}{3.5} = \\frac{2.3}{3.5}$$\nTo express this as a decimal rounded to four significant figures, we perform the division:\n$$r \\approx 0.657142857...$$\nRounding to four significant figures, we get:\n$$r = 0.6571$$\n\nNext, we must determine if the patient meets the criteria for an early partial renal response. This requires all three of the following conditions to be true simultaneously:\n(i) $r \\geq 0.5$\n(ii) $x_{12}  3.0$\n(iii) The relative decline in eGFR is less than $0.2$ of a baseline.\n\nWe will check each condition systematically.\n\nCondition (i): $r \\geq 0.5$\nOur calculated value for $r$ is $0.6571$. The inequality is $0.6571 \\geq 0.5$, which is true. This condition is met.\n\nCondition (ii): $x_{12}  3.0$\nThe given value for the $12$-week UPC is $x_{12} = 1.2$. The inequality is $1.2  3.0$, which is true. This condition is met.\n\nCondition (iii): The relative decline in eGFR is less than $0.2$.\nThe relative decline in eGFR can be calculated in a manner analogous to the fractional reduction in proteinuria. Let us denote the relative decline in eGFR as $r_{g}$.\n$$r_{g} = \\frac{g_{0} - g_{12}}{g_{0}}$$\nSubstituting the given eGFR values:\n$$r_{g} = \\frac{68 - 66}{68} = \\frac{2}{68} = \\frac{1}{34}$$\nTo evaluate the inequality, we can convert this fraction to a decimal:\n$$r_{g} = \\frac{1}{34} \\approx 0.0294117...$$\nThe condition is $r_{g}  0.2$. The inequality is $0.0294117...  0.2$, which is true. This condition is met.\n\nSince all three conditions—(i), (ii), and (iii)—are satisfied, the patient does meet the working definition of an early partial renal response at $12$ weeks.\n\nThe problem asks to report only the value of $r$, rounded to four significant figures. This value has been calculated as $0.6571$.", "answer": "$$\\boxed{0.6571}$$", "id": "4864995"}, {"introduction": "Lupus nephritis is a dynamic disease, and a patient's renal pathology can change over time. This advanced scenario simulates a common and complex clinical challenge: a patient who relapses on therapy with new, concerning clinical features. This practice will test your understanding of histologic transformation—the potential for a non-proliferative lesion to convert to a more aggressive proliferative one—and emphasizes the crucial role of a repeat kidney biopsy in guiding high-stakes therapeutic decisions [@problem_id:4864959].", "problem": "A $28$-year-old woman with systemic lupus erythematosus (SLE) and International Society of Nephrology/Renal Pathology Society (ISN/RPS) class $\\mathrm{V}$ lupus nephritis (LN) diagnosed $18$ months ago achieved a partial renal response to mycophenolate mofetil (MMF) up to $3$ g/day plus hydroxychloroquine: her proteinuria fell from $5.2$ g/day to $1.5$ g/day and serum creatinine stabilized at $0.9$ mg/dL over $9$ months. Over the last $6$ months, despite reported adherence, her proteinuria has risen to $3.2$ g/g creatinine with new microscopic hematuria and occasional red blood cell casts, and serum creatinine increased to $1.6$ mg/dL. Complement levels are decreased and anti–double-stranded deoxyribonucleic acid (anti-dsDNA) titers are increased compared with prior values. The treating team is considering adding a calcineurin inhibitor versus switching to cyclophosphamide, and debates whether a repeat kidney biopsy is necessary.\n\nWhich statement best justifies performing a repeat kidney biopsy in this apparent treatment resistance and correctly links plausible histologic evolution to a change in therapy?\n\nA. A repeat biopsy is indicated because clinical and serologic indices cannot reliably distinguish ongoing inflammatory activity from chronic scarring or a new lesion; if biopsy reveals transformation from class $\\mathrm{V}$ to proliferative class $\\mathrm{III}$/$\\mathrm{IV}$ or crescents with a high activity index, induction with high-dose glucocorticoids plus a proliferative LN regimen (cyclophosphamide or MMF-based) is appropriate, whereas predominant chronicity with low activity should prompt avoidance of further escalation and focus on supportive care.\n\nB. A repeat biopsy is unnecessary because complement and anti-dsDNA levels accurately track renal histology; with low complement and high anti-dsDNA, intensification of immunosuppression is indicated regardless of pathology.\n\nC. A repeat biopsy is indicated only when proteinuria exceeds $8$ g/day; regardless of histology, the preferred next step is to combine MMF with a calcineurin inhibitor.\n\nD. A repeat biopsy is indicated mainly to stage interstitial fibrosis for prognosis; irrespective of proliferative lesions, a membranous classification dictates continuation of antiproteinuric therapy alone without changing immunosuppression.\n\nE. A repeat biopsy should be pursued only if antiphospholipid antibodies are positive; if thrombotic microangiopathy is found, plasmapheresis is the standard next step rather than altering immunosuppression.", "solution": "This problem describes a realistic and clinically important scenario in the management of lupus nephritis (LN). The patient is a $28$-year-old woman with known International Society of Nephrology/Renal Pathology Society (ISN/RPS) class $\\mathrm{V}$ lupus nephritis, which is pure membranous nephropathy. She had a partial response to mycophenolate mofetil (MMF) but is now experiencing a disease flare, characterized by:\n1. Rising serum creatinine from $0.9$ mg/dL to $1.6$ mg/dL.\n2. Worsening proteinuria from a nadir of $1.5$ g/day to $3.2$ g/g creatinine.\n3. New nephritic urinary sediment, including microscopic hematuria and red blood cell (RBC) casts.\n4. Serologic activity, with decreased complement levels and increased anti-dsDNA titers.\n\nThe presence of RBC casts and a significant rise in serum creatinine are classic features of a proliferative glomerulonephritis, which are not typical for pure class $\\mathrm{V}$ (membranous) LN. This clinical picture is highly suspicious for a histologic transformation from a non-proliferative lesion (class $\\mathrm{V}$) to a proliferative lesion (class $\\mathrm{III}$ or $\\mathrm{IV}$, or mixed class $\\mathrm{V}$+$\\mathrm{III}$ or $\\mathrm{V}$+$\\mathrm{IV}$).\n\nThe central clinical question is whether to empirically escalate therapy or to perform a repeat kidney biopsy to guide the decision. Empiric treatment is risky because the underlying pathology is unknown. The patient's worsening could be due to:\na) Active proliferative glomerular disease (e.g., class $\\mathrm{III}$/$\\mathrm{IV}$ LN). This requires aggressive induction immunosuppression.\nb) Progressive, irreversible scarring (chronicity) with little active inflammation. In this case, escalating immunosuppression would be futile and cause unnecessary toxicity.\nc) Refractory class $\\mathrm{V}$ disease without proliferation, or another pathology entirely (e.g., thrombotic microangiopathy).\n\nClinical and serological markers, while suggestive of a flare, cannot reliably distinguish between these possibilities. Therefore, a repeat kidney biopsy is the standard of care in this situation to establish the current activity and chronicity of the renal lesion and to detect any class transformation. The biopsy findings will directly dictate the therapeutic plan.\n\nNow, let us evaluate each option.\n\nA. A repeat biopsy is indicated because clinical and serologic indices cannot reliably distinguish ongoing inflammatory activity from chronic scarring or a new lesion; if biopsy reveals transformation from class $\\mathrm{V}$ to proliferative class $\\mathrm{III}$/$\\mathrm{IV}$ or crescents with a high activity index, induction with high-dose glucocorticoids plus a proliferative LN regimen (cyclophosphamide or MMF-based) is appropriate, whereas predominant chronicity with low activity should prompt avoidance of further escalation and focus on supportive care.\nThis option provides a logically and medically sound rationale. It correctly identifies the limitations of non-histologic markers. It posits the most likely and clinically important transformation (to proliferative class $\\mathrm{III}$/$\\mathrm{IV}$) and links it to the correct therapeutic strategy (aggressive induction for proliferative LN). It also correctly identifies the alternative finding of predominant chronicity and links it to the appropriate conservative management. This reasoning is the cornerstone of modern LN management.\n\nB. A repeat biopsy is unnecessary because complement and anti-dsDNA levels accurately track renal histology; with low complement and high anti-dsDNA, intensification of immunosuppression is indicated regardless of pathology.\nThis statement is factually incorrect. There is a well-documented discordance between serologic markers and renal histology in a significant subset of patients with LN. A decision to intensify immunosuppression \"regardless of pathology\" is contrary to the principles of evidence-based medicine, as it ignores the critical distinction between active, reversible inflammation and irreversible, chronic damage. Such a strategy would expose patients with extensive scarring to the significant toxicities of drugs like cyclophosphamide or high-dose MMF without the potential for benefit.\n\nC. A repeat biopsy is indicated only when proteinuria exceeds $8$ g/day; regardless of histology, the preferred next step is to combine MMF with a calcineurin inhibitor.\nThis statement is flawed in two ways. First, the indication for a repeat biopsy is not based on an arbitrary proteinuria threshold (e.g., $8$ g/day) but on a clinically significant change in status, particularly the development of nephritic features like rising creatinine and RBC casts, as seen in this patient. Second, the therapeutic recommendation to combine MMF with a calcineurin inhibitor \"regardless of histology\" is inappropriate. This combination is a recognized therapy for refractory *membranous* (class $\\mathrm{V}$) LN but is not the standard induction regimen for severe *proliferative* (class $\\mathrm{III}$/$\\mathrm{IV}$) LN, which is the primary concern here. The choice of therapy must be guided by the histology.\n\nD. A repeat biopsy is indicated mainly to stage interstitial fibrosis for prognosis; irrespective of proliferative lesions, a membranous classification dictates continuation of antiproteinuric therapy alone without changing immunosuppression.\nThis statement is incorrect. While assessing fibrosis (chronicity) is an important function of the biopsy, the primary, urgent indication in this scenario is to assess for active, treatable proliferative lesions. The claim to act \"irrespective of proliferative lesions\" is a grave error; the presence of such lesions is the most critical finding that would mandate a change in therapy. Furthermore, for a patient already on immunosuppression (MMF) who is flaring, continuing \"antiproteinuric therapy alone\" is an inadequate response.\n\nE. A repeat biopsy should be pursued only if antiphospholipid antibodies are positive; if thrombotic microangiopathy is found, plasmapheresis is the standard next step rather than altering immunosuppression.\nThis statement incorrectly restricts the indication for biopsy. A class transformation to proliferative LN is a common reason for a flare and is independent of antiphospholipid antibody status. While thrombotic microangiopathy (TMA) is on the differential diagnosis, especially if antiphospholipid syndrome is suspected, it is not the only or most common possibility. Additionally, the management of lupus-associated TMA is complex and often involves modulating immunosuppression in addition to other measures like plasmapheresis, so stating that immunosuppression would not be altered is an oversimplification.", "answer": "$$\\boxed{A}$$", "id": "4864959"}]}